Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins

FW Asselbergs*, P van der Harst, GAJ Jessurun, RA Tio, WH van Gilst

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Citations (Scopus)

Abstract

Impaired endothelial function is recognised as one of the earliest events of atherogenesis. Endothelium-dependent vasomotion has been the principal method to assess endothelial function. In this article, we will discuss the clinical value of the different techniques to evaluate endothelium-dependent vasomotion. To date, there seems not to be a simple and reliably endothelial function test to identify asymptomatic subjects at increased risk for cardiovascular disease in clinical practice. Recent studies indicate that pharmacological interventions, in particular with ACE-inhibitors and statins, might improve endothelial function. However, there is no solid evidence that improvement of endothelial function is a necessity for the observed reduction in cardiovascular events by these compounds. Overall, at this moment, there is no place in clinical practice for the use of endothelial function as a method for risk assessment or target of pharmacological interventions. (c) 2005 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)125-140
Number of pages16
JournalVascular pharmacology
Volume42
Issue number3
DOIs
Publication statusPublished - Feb-2005

Keywords

  • endothelial function
  • acetylcholine
  • risk factors
  • prognosis
  • ACE-inhibitors
  • statins
  • CORONARY-ARTERY-DISEASE
  • ENDOTHELIUM-DEPENDENT VASODILATION
  • CONVERTING ENZYME-INHIBITION
  • LOW-DENSITY-LIPOPROTEIN
  • FLOW-MEDIATED VASODILATION
  • NITRIC-OXIDE SYNTHASE
  • TYPE-2 DIABETIC-PATIENTS
  • COLD PRESSOR TEST
  • CHOLESTEROL-LOWERING THERAPY
  • FOREARM RESISTANCE VESSELS

Cite this